Works by Kim, Kyung‐Soo


Results: 196
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2096, doi. 10.1111/dom.15080
    By:
    • Yang, Ye Seul;
    • Min, Kyung Wan;
    • Park, Seok‐O;
    • Kim, Kyung‐Soo;
    • Yu, Jae Myung;
    • Hong, Eun‐Gyoung;
    • Cho, Sung Rae;
    • Won, Kyu Chang;
    • Kim, Yong Hyun;
    • Oh, Seungjoon;
    • Choi, Sung Hee;
    • Koh, Gwanpyo;
    • Huh, Wan;
    • Kim, Su Young;
    • Park, Kyong Soo
    Publication type:
    Article
    12

    Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1865, doi. 10.1111/dom.15046
    By:
    • Kwak, Soo Heon;
    • Han, Kyung Ah;
    • Kim, Kyung‐Soo;
    • Yu, Jae Myung;
    • Kim, EunSook;
    • Won, Jong Chul;
    • Kang, Jun Goo;
    • Chung, Choon Hee;
    • Oh, Seungjoon;
    • Choi, Sung Hee;
    • Won, Kyu Chang;
    • Kim, Sin Gon;
    • Cho, Seung Ah;
    • Cho, Bo Young;
    • Park, Kyong Soo
    Publication type:
    Article
    13

    Front Cover.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. C1, doi. 10.1111/dom.14939
    By:
    • Moon, Sun Joon;
    • Kim, Kyung‐Soo;
    • Lee, Woo Je;
    • Lee, Mi Yeon;
    • Vigersky, Robert;
    • Park, Cheol‐Young
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50